Adjuvant Pembrolizumab: A New Option for High-Risk Muscle-Invasive Urothelial Cancer
Adjuvant use of the PD-1 inhibitor pembrolizumab achieved a statistically significant and clinically meaningful improvement in disease-free survival in...
Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers
A novel MDM2 inhibitor has demonstrated antitumor activity in progressive salivary cancer, particularly adenoid cystic carcinoma, according to data presented...
Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC
The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, the Pulmonary Pathology Society...
Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer
On April 18, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor alectinib (Alecensa) for adjuvant treatment after tumor resection...
Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations
According to recent studies, the incidence of early-onset cancers—often defined as those diagnosed in individuals younger than age 50—is on the rise...
Susan Faye Dent: Cardio-Oncology Is a Growing Subspecialty, but Where Are the Oncologists?
Kelly Hewitt and Laura J. Esserman: Reframing DCIS as an Opportunity for Cancer Prevention
Garth Strohbehn, Allen Lichter, and Mark Ratain: Sotorasib, the Poster Child for Project Optimus
Kevin B. Knopf and Charles L. Bennett: Generic Drug Shortages and Essential Cancer Medicines
Stuart M. Lichtman: All Adult Oncologists Are Geriatric Oncologists
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Targeting Rare, Actionable Alterations in Advanced Non–Small Cell Lung Cancer
Study Finds Need to Improve Knowledge About Palliative Care Among U.S. Adults
The use of palliative care in hospitals in the United States has steadily risen over the past decade, with almost universal access to services in large hospitals and academic medical centers. Despite this increased access and recommendations from ASCO that all patients with advanced cancer receive...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Addition of Gemtuzumab Ozogamicin to Conventional Background Chemotherapy in Pediatric Patients With KMT2A-Rearranged AML
As reported in the Journal of Clinical Oncology by Pollard et al, a subgroup of pediatric patients with KMT2A-rearranged acute myeloid leukemia (AML) in the phase III Children’s Oncology Group AAML0531 trial had improved outcomes with the addition of the CD33-targeting agent gemtuzumab ozogamicin...
Overall Survival Benefit With Upfront Daratumumab Plus Lenalidomide/Dexamethasone for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma
In an updated analysis of the phase III MAIA trial, the addition of daratumumab to lenalidomide and dexamethasone resulted in a statistically significant overall survival benefit over lenalidomide/dexamethasone alone in patients with newly diagnosed multiple myeloma who are ineligible for...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Effect of the COVID-19 Pandemic on Delivery of Oncology Services in India
In a study reported in The Lancet Oncology, Ranganathan et al quantified the enormous impact of the COVID-19 pandemic on delivery of cancer services in India. Study Details The study involved data from 41 cancer centers across the nation. The delivery of oncology services between March 1 and May...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
